Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-20. Numbers and descriptions here follow the published literature rather than marketing material.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
There are a variety of bioreactors designed for 3D cell cultures. There are small plastic cylindrical chambers, as well as glass chambers, with regulated internal humidity and moisture specifically engineered for the purpose of growing cells in three dimensions. The bioreactor uses bioactive synthetic materials such as polyethylene terephthalate membranes to surround the spheroid cells in an environment that maintains high levels of nutrients. They are easy to open and close, so that cell spheroids can be removed for testing, yet the chamber is able to maintain 100% humidity throughout. This humidity is important to achieve maximum cell growth and function. The bioreactor chamber is part of a larger device that rotates to ensure equal cell growth in each direction across three dimensions. QuinXell Technologies now under Quintech Life Sciences from Singapore has developed a bioreactor known as the TisXell Biaxial Bioreactor which is specially designed for the purpose of tissue engineering. It is the first bioreactor in the world to have a spherical glass chamber with biaxial rotation; specifically to mimic the rotation of the fetus in the womb; which provides a conducive environment for the growth of tissues. Multiple forms of mechanical stimulation have also been combined into a single bioreactor. Using gene expression analysis, one academic study found that applying a combination of cyclic strain and ultrasound stimulation to pre-osteoblast cells in a bioreactor accelerated matrix maturation and differentiation.
=== Other pharmaceuticals === In 2017, a two-dose HBV vaccine for adults, the hepatitis B vaccine Heplisav-B gained U.S. Food and Drug Administration (FDA) approval. It uses recombinant HB surface antigen, similar to previous vaccines, but includes a novel CpG 1018 adjuvant, a 22-mer phosphorothioate-linked oligodeoxynucleotide. It was non-inferior concerning immunogenicity. Phosphorothioate groups are also used in synthetic CpG oligodeoxynucleotides.
Chinese traditional medicine uses the oil of crocodiles for other conditions such as bronchitis, allergy, skin problems, high blood pressure, and cancer. Crocodile oil is also prescribed to treat burns, skin ulcers and cancer, coughs, and asthma in Madagascar. There is also evidence of crocodile oil being used traditionally in South Africa for skin condition treatments for eczema and rashes and for promoting wound healing. Crocodile oil is used in Mexico for treatment of illnesses such as asthma, emphysema, and influenza.
== Analogues == Nicotinamide cofactor analogues have been synthesized with varying substituents on the dihydropyridine ring to tune their redox potential and stability, to replace NADH or NADPH in certain enzymatic reactions. These synthetic cofactors have been used as early as 1937 to better understand the mechanisms of enzymatic reactions, in particular of alcohol dehydrogenases. These cofactor analogues can serve as an alternative to traditional cofactor regeneration techniques and be used in orthogol pathways.
Sources: en.wikipedia.org
== Cultivation == Buckwheat is a short-season crop that grows well in low-fertility or acidic soils; too much fertilizer – especially nitrogen – reduces yields, and the soil must be well drained. In hot climates buckwheat can be grown only by sowing late in the season, so that it blooms in cooler weather. The presence of pollinators greatly increases yield. Nectar from flowering buckwheat produces a dark-colored honey. The buckwheat plant has a branching root system with a primary taproot that reaches deeply into moist soil. It grows 75 to 125 centimetres (30 to 50 inches) tall. Buckwheat has tetrahedral seeds and produces a flower that is usually white, although can also be pink or yellow. Buckwheat branches freely, as opposed to tillering or producing suckers, enabling more complete adaption to its environment than other cereal crops. Buckwheat is raised for grain where only a brief time is available for growth, either because the buckwheat is an early or a second crop in the season, or because the total growing season is limited. It establishes quickly, which suppresses summer weeds, and can be a reliable cover crop in summer to fit a small slot of warm season. Buckwheat has a growing period of only 10–12 weeks and it can be grown in high latitude or northern areas. Buckwheat is sometimes used as a green manure, as a plant for erosion control or as wildlife cover and feed. It may be used as a pollen and nectar source to increase natural predator numbers for biological control of crop pests.
===== Indirect thrombin inhibitors ===== Indirect thrombin inhibitors bind to antithrombin to enhance the rate of inactivation of clotting factors, indirectly inactivating thrombin through actions on antithrombin. Heparin is a widely used anticoagulant. It is administered intravenously (into a vein) or subcutaneously (below the skin). Heparin can exert an immediate anti-clotting effect which is useful for the treatment of acute symptoms. Besides, heparin therapy is indicated for anticoagulation during pregnancy as it does not cross the placenta and is not associated with fetal malformations.
1956: The association "La Maternité Heureuse," which would become the French Movement for Family Planning (MFPF) in 1960, is founded; its goals include sex education and advocacy for the right to contraception and abortion. December 11, 1956: Law on the housewife allowance, extended beyond agricultural professions. March 25, 1957: Treaty of Rome establishing the European Economic Community; it includes a principle of equal pay for men and women for identical work.
Sources: en.wikipedia.org
==== Eliminated in primary ==== Rob Altman, U.S. Army veteran Ben Bius, businessman, candidate for Texas's 12th House of Representatives district in 2022 and 2024, and nominee in 2000 Rob Brown, pastor (previously ran in the 17th district) Brandon Hawbraker, software engineer Jessica Karlsruher, lobbyist (previously filed to run in the 21st district) Kara King, mayor of Bee Cave Scott MacLeod, U.S. Army veteran Jenny Garcia Sharon, volunteer caregiver Jeremy Story, minister
== Applications == The Information divided AI agents into seven archetypes: business-task agents, for acting within enterprise software; conversational agents, which act as chatbots for customer support; research agents, for querying and analyzing information (such as OpenAI Deep Research); analytics agents, for analyzing data to create reports; software developer or coding agents (such as Cursor); domain-specific agents, which include specific subject matter knowledge; and web browser agents (such as OpenAI Operator). By mid-2025, AI agents were being used in video game development, gambling (including sports betting), cryptocurrency wallets (including cryptocurrency trading and meme coins) and social media. In August 2025, New York Magazine described software development as the most definitive use of AI agents. The Information noted AI coding agents and customer support as the primary uses of AI by businesses by October 2025, although a decline in the expectations of AI capabilities was also noted. In November 2025, The Wall Street Journal reported that few companies that deployed AI agents have received a return on investment.
Reverse transport, or transporter reversal, is a phenomenon in which the substrates of a membrane transport protein are moved in the opposite direction to that of their typical movement by the transporter. Transporter reversal typically occurs when a membrane transport protein is phosphorylated by a particular protein kinase, which is an enzyme that adds a phosphate group to proteins.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.